Immunotherapy Drugs Market

Approval is the Key Growth Strategy Adopted by Players Operating in the Immunotherapy Drugs Market

Immunotherapy Drugs Market, by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific)-Global Forecast to 2021

F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (U.S.), and Abbvie, Inc. (U.S.) are the leading players in the global immunotherapy drugs market. The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include Amgen Inc. (U.S.), Merck & Co., Inc. (U.S), and GlaxoSmithKline (U.K.).

F. Hoffmann-La Roche AG (Switzerland) accounted for the largest share of 19.1% of the global immunotherapy drugs market in 2015. The company focuses on the strategy of expansion and product approvals to maintain its footprint in the immunotherapy drugs market. In accordance with this, the company widened its immuno-oncology portfolio with FDA and European marketing authorization approvals for Gazyvaro and Kadcyla, which are used in the treatment of chronic lymphocytic leukemia and breast cancer, respectively. Similarly, in 2016, the company also received FDA approval for TECENTRIQ and European Commissionís approval for Avastin in combination with Tarceva used for treatment of metastatic non-small cell lung cancer.

Johnson & Johnson (U.S.) was the second-largest player in the global immunotherapy drugs market with a market share of 13.1% in 2015. The company mainly focuses on inorganic strategies such as acquisitions, collaborations and approvals to sustain its position in the immunotherapy drugs market. In November 2016, Janssen Biotech, Inc. a division of J&J (U.S.) entered into clinical trial collaboration with Onyx Pharmaceuticals, Inc., a subsidiary of Amgen (U.S.). Similarly, in November 2015, DARZALEX injection, the first human anti-CD38 monoclonal antibody from Janssen Biotech, Inc. has been approved by US-FDA for intravenous infusion for the treatment of patients with multiple myeloma.

Companies in the immunotherapy drugs market are majorly focusing on drugs approval for strengthening their market share; this strategy accounted for ~43% of the total number of strategic developments undertaken by key players in this market.

Related Reports:

Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

Contact:
Mr. Rohan
Markets and Markets 
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Report Code
PH 3926
RI Published ON
1/4/2017
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunotherapy Drugs Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved